ClinicalTrials.gg

Program

risovalisib

Also written as “CYH33” and “CYH33 for tablet”.

Its studies are mostly in Ovarian Neoplasms · Vascular Malformations, led by Haihe Biopharma.

Furthest: phase 2, since Aug 30, 20214 company-led studies, 2 open or runningNext primary completion: Dec 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haihe Biopharma42 open or runningphase 2since Aug 30, 2021May 22, 2018Dec 31, 2029phase 2 · NCT06975618

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT03544905 · 206 enrolled · China
  2. Aug 25, 2020Phase 1 study in Ovarian NeoplasmsNCT04586335 · 24 enrolled · United States, Australia, China
  3. Aug 30, 2021Phase 2 study in Ovarian NeoplasmsNCT05043922 · 93 enrolled · China, Japan
  4. Apr 28, 2025Phase 2 study in PIK3CA-Related Overgrowth Spectrum (PROS)NCT06975618 · 141 planned · China, Japan

Ahead

  1. Dec 31, 2029Primary completion: phase 2 study in PIK3CA-Related Overgrowth Spectrum (PROS)NCT06975618

TargetBeta

PIK3CA →read by rule
“An orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), ”NCIt, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06975618PIK3CA-Related Overgrowth Spectrum (PROS) · China, Japan2RecruitingDec 31, 2029141
NCT05043922Ovarian Neoplasms · China, Japan2Active, not recruitingJul 31, 202493
NCT04586335Ovarian Neoplasms · United States, Australia, China1TerminatedFeb 15, 202324
NCT03544905Advanced Solid Tumors · China1CompletedDec 4, 2024206

How it is read

Names in the registry

  • “CYH33”, 3 entries
  • “CYH33 for tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.